15.04.2013 Views

Newsjournal body.qxp - College of Chemistry - University of ...

Newsjournal body.qxp - College of Chemistry - University of ...

Newsjournal body.qxp - College of Chemistry - University of ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Jane Scheiber photo<br />

Chemical Engineering News<br />

by Alexis T. Bell,<br />

Chair<br />

and<br />

Warren and Katharine<br />

Schlinger Distinguished<br />

Pr<strong>of</strong>essor<br />

DEVELOPING OUR<br />

POTENTIAL<br />

Spring is the season <strong>of</strong> renewal and rededication. While budgetary shortfalls remain a subject <strong>of</strong><br />

concern, our faculty has continued to move forward in its efforts to provide our students exciting<br />

educational and research experiences. The bright light just ahead is the Governor’s compact with<br />

the President <strong>of</strong> the <strong>University</strong> <strong>of</strong> California, which promises to restore some <strong>of</strong> the lost state<br />

support. In the meantime, the department’s faculty members continue to gain recognition and to<br />

New Department Chair(s)<br />

After nearly four years <strong>of</strong> service, Pr<strong>of</strong>essor Arup<br />

Chakraborty decided to step down from his position as<br />

department chair. We all owe a debt <strong>of</strong> immense gratitude<br />

to Arup for his tireless efforts during a period <strong>of</strong> budgetary<br />

challenges for the <strong>University</strong> and the department.<br />

Thanks to his fine work, the department has not suffered<br />

and remains exceptionally strong. The <strong>University</strong> has<br />

appointed Pr<strong>of</strong>essor Jeffrey Reimer to become the new<br />

chair; however, he will not assume this position until July<br />

1, 2006, since he plans to take a sabbatical leave during the<br />

2005-2006 academic year. To fill the gap, I have agreed to<br />

serve as chair for the 15-month period between April 1 <strong>of</strong><br />

this year and June 30 <strong>of</strong> next year.<br />

National Medal <strong>of</strong> Science<br />

Pr<strong>of</strong>essor John Prausnitz was selected to receive the<br />

National Medal <strong>of</strong> Science, the nation’s highest honor in<br />

science and technology, in recognition <strong>of</strong> his pioneering<br />

work on the development <strong>of</strong> molecular thermodynamics<br />

and its application to a broad range <strong>of</strong> industrial problems.<br />

The Medal was presented to John at a ceremony hosted by<br />

President George Bush on March 14 at the White House.<br />

While John retired formally from the department on<br />

July 1, 2004, he has been appointed as a Pr<strong>of</strong>essor <strong>of</strong> the<br />

Graduate School and remains highly active in research.<br />

NAE Election<br />

Pr<strong>of</strong>essor Harvey Blanch was elected to the National<br />

Academy <strong>of</strong> Engineering (NAE) and will be inducted into<br />

the Academy next October. This high honor is given in<br />

recognition <strong>of</strong> Harvey’s excellent research and leadership<br />

in the field <strong>of</strong> biochemical engineering. With his<br />

election, the total number <strong>of</strong> NAE members in the department<br />

now stands at six.<br />

Synthetic Biology<br />

Pr<strong>of</strong>essor Jay Keasling will benefit from a<br />

$43 million grant from the Bill and Melinda Gates<br />

Foundation to develop a more affordable approach to the<br />

synthesis <strong>of</strong> artemisinin, an antimalarial drug for use<br />

especially in the third world. Efforts on this project will<br />

be carried out at Berkeley in partnership with the<br />

Institute for OneWorld Health, the first non-pr<strong>of</strong>it pharmaceutical<br />

company in the U.S., and Amyris, a new<br />

biotech firm. OneWorld Health will perform the drug<br />

development and regulatory work to demonstrate the<br />

bioequivalence <strong>of</strong> microbially-produced artemisinin derivative<br />

to the drug’s natural form, whereas Amyris will develop<br />

the process for industrial fermentation and commercialization.<br />

Jay’s work in this area was recently singled<br />

CONQUERING DISEASE.<br />

Jay Keasling’s work on developing a<br />

malaria vaccine has been selected by<br />

Technology Review as one <strong>of</strong> the “10<br />

Emerging Technologies That Will Change<br />

Your World.”<br />

4 BERKELEY COLLEGE OF CHEMISTRY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />

coutrtesy Bioengineering

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!